With shorter half-lives and more predictable effects, direct oral anticoagulants (DOACs) could help simplify perioperative treatment decisions for patients with non-valvular atrial fibrillation (NVAF), suggests a meta-analysis published May 24 in Circulation.

Severe and active atopic eczema in adulthood is associated with an increased risk for developing cardiovascular disease (CVD), including stroke, heart failure, myocardial infarction (MI) and atrial fibrillation (AFib), according to a new study published May 23 in The BMJ.

Human growth hormone showed the potential to improve the memory and cognitive function of mice post-stroke, raising the possibility of a similar treatment for humans.

Individuals with a combination of vascular risk factors and higher levels of beta-amyloid protein in the brain may be on a speedier path of cognitive decline, suggests a study published May 21 in JAMA Neurology.

Senior citizens who reported exercising at least four times a week throughout their lives showed decreased age-related arterial stiffness when compared to more sedentary individuals, according to a study published May 20 in the Journal of Physiology.

REDWOOD CITY, Calif., May 23, 2018 - Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its next generation Pantheris® Lumivascular atherectomy system, the first-ever image-guided atherectomy device for the treatment of peripheral artery disease.

The FlowTriever System has become the first thrombectomy device designed to treat pulmonary embolism (PE) to be cleared by the FDA, Inari Medical announced in a May 21 press release.

Patients who suffer minor ischemic stroke or a transient ischemic attack (TIA) can lower the risk for a major stroke within 90 days by taking both clopidogrel and aspirin, according to a study published online May 16 in The New England Journal of Medicine.